Last reviewed · How we verify
sirolimus, tacrolimus, mycophenolate mofetil
This triple immunosuppressive regimen inhibits T-cell proliferation and activation through distinct mechanisms to prevent organ rejection.
This triple immunosuppressive regimen inhibits T-cell proliferation and activation through distinct mechanisms to prevent organ rejection. Used for Organ transplant rejection prevention (kidney, heart, liver transplantation).
At a glance
| Generic name | sirolimus, tacrolimus, mycophenolate mofetil |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Immunosuppressive agent combination |
| Target | mTOR, calcineurin, IMPDH |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Sirolimus inhibits mTOR signaling to block T-cell proliferation; tacrolimus inhibits calcineurin to prevent IL-2 production and T-cell activation; mycophenolate mofetil inhibits inosine monophosphate dehydrogenase to selectively suppress lymphocyte proliferation. Together, these agents provide complementary immunosuppression for transplant rejection prevention.
Approved indications
- Organ transplant rejection prevention (kidney, heart, liver transplantation)
Common side effects
- Infection
- Nephrotoxicity
- Hyperglycemia
- Hypertension
- Gastrointestinal disturbance
- Bone marrow suppression
- Hyperlipidemia
Key clinical trials
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy (PHASE3)
- A Study to Evaluate Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256) (PHASE2)
- Allo HSCT for High Risk Hemoglobinopathies (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
- Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies (PHASE1, PHASE2)
- Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer (PHASE4)
- The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients (PHASE2)
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: